Toronto, ON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc.(CSE: ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the United States Food and Drug Administration ("FDA") for its first Investigational New Drug ("IND") application.
Xpira Pharmaceuticals is a leader in the development of psychedelic medicines for the treatment of eating disorders, particularly for patients who have not responded well to conventional therapies. Following this week’s announced FDA approval, Xpira will commence a Phase 2a clinical trial to study the efficacy of psilocybin-assisted therapy in patients diagnosed with the eating disorder Anorexia Nervosa.
Anorexia Nervosa is a deadly mental illness, and currently has no approved therapeutic regimen. Xpira hopes that its latest phase of clinical trials will result in the creation of a successful treatment plan for patients with the eating disorder.
“We have always been impressed with Xpira’s commitment to safety, efficacy, and clinical expertise,” said Alexander Somjen, CEO of Origin Therapeutics. “They intend to be a global leader in the psychedelic treatment of eating disorders, and today’s announcement is another step in the right direction.”
“With FDA approval for its IND application, Xpira has cleared a major hurdle on the path to development - and, ultimately, commercialization - of a new treatment for Anorexia Nervosa,” Mr. Somjen added. “We have full confidence in the team at Xpira and can’t wait to see what this next phase of clinical trials will bring.”
About Xpira
Xpira Pharmaceuticals Inc ("Xpira") is positioned to be a global leader in development, production, and marketing of psychedelic-based medicines with clinically proven efficacy. Our mission is to have a meaningful impact on the lives of patients suffering from mental conditions by developing high quality proprietary therapeutic treatments with a special focus on eating disorders.
Xpira's team is composed of industry leaders in North America and the Netherlands, with substantial experience in eating disorders, drug development, intellectual property ("IP"), registration, product commercialization and Specialty Pharma.
About Origin Therapeutics
Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector.
Learn more at www.originpsychedelics.com
For Further Information:
Alexander Somjen
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc.
www.originpsychedelics.com
info@originpsychedelics.com
Cautionary Note
All information contained in this news release with respect to Xpira was supplied by Xpira for inclusion herein, and Origin’s directors and officers have relied on Xpira for such information.
Forward-Looking Information and Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
